Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance

Clinical and Experimental Hypertension

Volumn 30, Issue 5, 2008, Pages 309-314

  Suzuki, Katsunori ^a   Nakagawa, Osamu ^b   Aizawa, Yoshifusa ^c  

^a Saiseikai Niigata Second Hospital   (Japan)

^b Sanjo General Hospital   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Candesartan; IGT; Insulin secretion; Insulinogenic index

Indexed keywords

CANDESARTAN; GLUCOSE; IMMUNOREACTIVE INSULIN; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; INSULIN; INSULIN-SECRETING CELLS; MIDDLE AGED; TETRAZOLES; TIME FACTORS;

EID: 47549109249     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802269927     Document Type: Article

References (13)

1. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 diabetes mellitus: What guidance from recent controlled randomized trials? J Hypertens 2002;20:2099-2110.
2. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:30H-37H.
3. Oda T, Hirata M, Oshida Y, Han YQ, Koshinaka K, Sato Y. Effect of imidapril, an angiotensin-converting enzyme inhibitor, on fructose-induced insulin resistance in rats. Endocr J 2004;51:69-74.
4. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53:989-997.
5. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004;316:114-122.
6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report a WHO consultation. Diabet Med 1998;15:539-553.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
8. Matthews DR, Hosker JP, Rudenki AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.
9. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: Relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323-335.
10. Shao J, Iwashita N, Ikeda F, Ogihara T, Uchida T, Shimizu T, Uchino H, Hirose T, Kawamori R, Watada H. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun. 2006;344(4):1224-1233.
11. Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signal in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100:2158-2169.
12. Togashi N, Ura N, Higashimura K, et al. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000;18:1605-1610.
13. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonist reduces insulin resistance in obese Zucker rats. Hypertension 2001;38:884-890.